Role of enteral nutrition in the clinical care, management, and quality of life of patients with inflammatory bowel disease
Frontiers in Nutrition · 29.04.2026 · 13
DOI: 10.3389/fnut.2026.1759869 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Nutrition, online erschienen am 29.04.2026. Verfasst von Qian Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Second Affiliated Hospital of Soochow University, Suzhou, China. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Enteral nutrition (EN) is essential for Inflammatory Bowel Disease treatment. This applies mainly to Crohn’s disease (CD) and ulcerative colitis (UC) patients. The study evaluated the impact of EN treatment on clinical, nutritional, inflammatory, and quality of life outcomes in IBD patients. This study aimed to examine the association between EN therapy’s clinical, nutritional, inflammatory, and Quality of Life (QoL) effects on Inflammatory Bowel Disease patients.
Methods
A retrospective study investigated 750 Chinese IBD patients. These patients had 400 CD and 350 UC diagnoses. Medical records provided data. EN formula, administration, calorie density, and duration were studied along with disease activity, nutritional markers including hemoglobin, albumin, and body mass index, and inflammatory indices like erythrocyte sedimentation rate. Validated IBDQ measures quality of life. Clinical remission was defined as a Crohn’s Disease Activity Index (CDAI) score < 150 for CD patients and a Mayo score ≤ 2 (with no individual subscore > 1) for UC patients, assessed after completion of EN therapy. Chi-square and t -tests were used for statistical analysis, with a significance level of p < 0.05.
Results
Baseline characteristics of 750 patients are comparable between groups. Elemental and semi-elemental formulas were more frequently prescribed in CD patients and were associated with higher caloric and protein intake ( p < 0.05). Approximately 60% of patients achieved clinical remission after 6 ± 2 weeks of EN therapy (62.5% CD vs. 57.1% UC). Improvements in BMI, albumin, hemoglobin, and CRP were observed in patients receiving EN, along with increased IBDQ scores. Adverse effects were minor (8%). Full adherence (OR = 2.15, p < 0.001) and longer EN duration (>6 weeks) were independently associated with higher odds of remission and QoL improvement.
Conclusion
EN therapy corresponded with clinical remission, improved nutritional markers, and reduced inflammation in IBD patients, particularly those with CD. These findings support the potential role of EN as a complementary strategy in IBD management; however, prospective randomized trials are further confirming these associations and standardize therapeutic protocols.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Zitieren
APA
Chen, Q., Zhu, Q., Chen, R., Zhou, S., & Tang, W. (2026). Role of enteral nutrition in the clinical care, management, and quality of life of patients with inflammatory bowel disease. Frontiers in Nutrition, 13. https://doi.org/10.3389/fnut.2026.1759869
Vancouver
Chen Q, Zhu Q, Chen R, Zhou S, Tang W. Role of enteral nutrition in the clinical care, management, and quality of life of patients with inflammatory bowel disease. Frontiers in Nutrition. 2026;13. doi:10.3389/fnut.2026.1759869
BibTeX
@article{Chen2026,
author = {Chen, Qian and Zhu, Qianlan and Chen, Ruidong and Zhou, Shuang and Tang, Wen},
title = {Role of enteral nutrition in the clinical care, management, and quality of life of patients with inflammatory bowel disease},
journal = {Frontiers in Nutrition},
year = {2026},
volume = {13},
doi = {10.3389/fnut.2026.1759869}
}
EUVIMED